source
- Blood centers can help biopharma scale cell and gene therapiesBlood centers have the donors, resources and community footprint drug sponsors need to solve supply chain issues around cell and gene therapies.BioSpace · 1h ago↗ source
- Summit and Akeso report ivonescimab extends lung cancer survival by eight months versus Keytruda in Phase 3 trialSummit Therapeutics and its partner Akeso said their experimental dual-target drug ivonescimab added about eight months of overall survival for patients with lung cancer compared with Merck's Keytr…